Attendee Dr. Steven Vogl, an oncologist who practices in the Bronx, New York, asked whether the conclusion from the current results is "that docetaxel is not a very good drug and that erlotinib is a terrible drug and we shouldn’t give it to these nonmutated patients anymore?"
After a slight pause, Dr. Garassino responded, "I think that you are right," to a round of laughter and applause.
TAILOR was sponsored by Agenzia Italiana del Farmaco. Dr. Garassino and her coauthors reported no disclosures. Dr. Solomon reported an advisory or consultant role with AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Lilly, Pfizer and Roche.